The DOI matches its Crossref record; 539 of the 539 references it cites were found in a registry or an index.
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Abstract
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor agents. However, their historic classification as antimitotics does not describe all their functions. Indeed, taxanes act in a complex manner, altering multiple cellular oncogenic processes including mitosis, angiogenesis, apoptosis, inflammatory response, and ROS production. On the one hand, identification of the diverse effects of taxanes on oncogenic signaling pathways provides opportunities to apply these cytotoxic drugs in a more rational manner. On the other hand, this may facilitate the development of novel treatment modalities to surmount anticancer drug resistance. In the latter respect, chemoresistance remains a major impediment which limits the efficacy of antitumor chemotherapy. Taxanes have shown impact on key molecular mechanisms including disruption of mitotic spindle, mitosis slippage and inhibition of angiogenesis. Furthermore, there is an emerging contribution of cellular processes including autophagy, oxidative stress, epigenetic alterations and microRNAs deregulation to the acquisition of taxane resistance. Hence, these two lines of findings are currently promoting a more rational and efficacious taxane application as well as development of novel molecular strategies to enhance the efficacy of taxane-based cancer treatment while overcoming drug resistance. This review provides a general and comprehensive picture on the use of taxanes in cancer treatment. In particular, we describe the history of application of taxanes in anticancer therapeutics, the synthesis of the different drugs belonging to this class of cytotoxic compounds, their features and the differences between them. We further dissect the molecular mechanisms of action of taxanes and the molecular basis underlying the onset of taxane resistance. We further delineate the possible modalities to overcome chemoresistance to taxanes, such as increasing drug solubility, delivery and pharmacokinetics, overcoming microtubule alterations or mitotic slippage, inhibiting drug efflux pumps or drug metabolism, targeting redox metabolism, immune response, and other cellular functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 539
Tyrosination of α‐tubulin controls the initiation of processive dynein–dynactin motility
McKenney, R. J., Huynh, W., Vale, R. D., & Sirajuddin, M. (2016) · The EMBO Journal · doi:10.15252/embj.201593071 · Cited by 232
Paulus, P., Stanley, E. R., Schäfer, R., Abraham, D., & Aharinejad, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3523 · Cited by 231
Meidhof, S., Brabletz, S., Lehmann, W., Preca, B., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404396 · Cited by 229
Jiang, J., Wang, K., Chen, Y., Chen, H., Nice, E. C., & Huang, C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.36 · Cited by 228
Komlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
Natural Taxanes: Developments Since 1828
Wang, Y.-F., Shi, Q.-W., Dong, M., Kiyota, H., Gu, Y.-C., & Cong, B. (2011) · Chemical Reviews · doi:10.1021/cr100147u · Cited by 226
Zhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
Self-citationClass III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer
Gan, P. P., Pasquier, E., & Kavallaris, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0509 · Cited by 221
Mechanisms of ROS modulated cell survival during carcinogenesis
Clerkin, J. S., Naughton, R., Quiney, C., & Cotter, T. G. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.029 · Cited by 219
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway
Strobel, T., Swanson, L., Korsmeyer, S., & Cannistra, S. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14094 · Cited by 216
Extracellular Vesicles – Biomarkers and Effectors of the Cellular Interactome in Cancer
Rak, J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00021 · Cited by 215
Huisman, M. T., Chhatta, A. A., van Tellingen, O., Beijnen, J. H., & Schinkel, A. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21013 · Cited by 211
O'Day, S., Gonzalez, R., Lawson, D., Weber, R., Hutchins, L., Anderson, C., Haddad, J., Kong, S., Williams, A., & Jacobson, E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1579 · Cited by 208
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer
Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12082252 · Cited by 208
Microtubule Regulation in Mitosis: Tubulin Phosphorylation by the Cyclin-dependent Kinase Cdk1
Fourest-Lieuvin, A., Peris, L., Gache, V., Garcia-Saez, I., Juillan-Binard, C., Lantez, V., & Job, D. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-07-0621 · Cited by 207
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy
Grogan, T., Spier, C., Salmon, S., Matzner, M., Rybski, J., Weinstein, R., Scheper, R., & Dalton, W. (1993) · Blood · doi:10.1182/blood.v81.2.490.490 · Cited by 207
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Self-citationRole of Focal Adhesion Kinase in Regulating YB–1–Mediated Paclitaxel Resistance in Ovarian Cancer
Kang, Y., Hu, W., Ivan, C., Dalton, H. J., Miyake, T., Pecot, C. V., Zand, B., Liu, T., Huang, J., Jennings, N. B., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt210 · Cited by 204
Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10)
Hopper-Borge, E., Chen, Z.-S., Shchaveleva, I., Belinsky, M. G., & Kruh, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3111 · Cited by 198
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Gan, L., Chen, S., Wang, Y., Watahiki, A., Bohrer, L., Sun, Z., Wang, Y., & Huang, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1504 · Cited by 197
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
Zhang, Y.-K., Wang, Y.-J., Gupta, P., & Chen, Z.-S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9757-1 · Cited by 196
Microtubules: A dynamic target in cancer therapy
Pasquier, E., & Kavallaris, M. (2008) · IUBMB Life · doi:10.1002/iub.25 · Cited by 195
Ni, J., Cozzi, P., Hao, J., Beretov, J., Chang, L., Duan, W., Shigdar, S., Delprado, W., Graham, P., Bucci, J., et al. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.09.008 · Cited by 195
NF-κB-mediated Induction of mdr1b Expression by Insulin in Rat Hepatoma Cells
Zhou, G., & Kuo, M. T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15174 · Cited by 193
Gaitanos, T. N., Buey, R. M., Díaz, J. F., Northcote, P. T., Teesdale-Spittle, P., Andreu, J. M., & Miller, J. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0771 · Cited by 193
Sayan, A. E., Griffiths, T. R., Pal, R., Browne, G. J., Ruddick, A., Yagci, T., Edwards, R., Mayer, N. J., Qazi, H., Goyal, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902042106 · Cited by 192
Yang, C., He, L., He, P., Liu, Y., Wang, W., He, Y., Du, Y., & Gao, F. (2015) · Medical Oncology · doi:10.1007/s12032-014-0352-6 · Cited by 189
Ajabnoor, G. M. A., Crook, T., & Coley, H. M. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.139 · Cited by 189
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
Self-citationStructure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1
Alam, A., Küng, R., Kowal, J., McLeod, R. A., Tremp, N., Broude, E. V., Roninson, I. B., Stahlberg, H., & Locher, K. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717044115 · Cited by 187
van der Zee, A. G., Hollema, H., Suurmeijer, A. J., Krans, M., Sluiter, W. J., Willemse, P. H., Aalders, J. G., & de Vries, E. G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.70 · Cited by 184
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells
Li, Z., Hu, S., Wang, J., Cai, J., Xiao, L., Yu, L., & Wang, Z. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.06.004 · Cited by 183
Tubulin isoform composition tunes microtubule dynamics
Vemu, A., Atherton, J., Spector, J. O., Moores, C. A., & Roll-Mecak, A. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-02-0124 · Cited by 183
Esser, L., Zhou, F., Pluchino, K. M., Shiloach, J., Ma, J., Tang, W.-K., Gutierrez, C., Zhang, A., Shukla, S., Madigan, J. P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755884 · Cited by 182
Borgnia, M. J., Eytan, G. D., & Assaraf, Y. G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.6.3163 · Cited by 180
Self-citationSnapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein
Szewczyk, P., Tao, H., McGrath, A. P., Villaluz, M., Rees, S. D., Lee, S. C., Doshi, R., Urbatsch, I. L., Zhang, Q., & Chang, G. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715000978 · Cited by 180
Drori, S., Eytan, G. D., & Assaraf, Y. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.1020m.x · Cited by 179
Self-citationAntisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol
Kavallaris, M., Burkhart, C. A., & Horwitz, S. B. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690507 · Cited by 179
The pharmacological bases of the antiangiogenic activity of paclitaxel
Bocci, G., Di Paolo, A., & Danesi, R. (2013) · Angiogenesis · doi:10.1007/s10456-013-9334-0 · Cited by 176
The multifaceted regulation and functions of PKM2 in tumor progression
Li, Z., Yang, P., & Li, Z. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.008 · Cited by 175
Recent advances in microtubule-stabilizing agents
Cao, Y.-N., Zheng, L.-L., Wang, D., Liang, X.-X., Gao, F., & Zhou, X.-L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.062 · Cited by 175
Genes amplified and overexpressed in human multidrug-resistant cell lines.
van der Bliek, A. M., Baas, F. F., der Velde-Koerts, T. V., et al. (1988) · PubMed · Cited by 173
Galsky, M. D., Dritselis, A., Kirkpatrick, P., & Oh, W. K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3254 · Cited by 173
The Pinene Path to Taxanes. 5. Stereocontrolled Synthesis of a Versatile Taxane Precursor
Wender, P. A., Badham, N. F., Conway, S. P., Floreancig, P. E., Glass, T. E., Gränicher, C., Houze, J. B., Jänichen, J., Lee, D., Marquess, D. G., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9635387 · Cited by 172
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 172
Self-citationKanda, Y., Nakamura, H., Umemiya, S., Puthukanoori, R. K., Appala, V. R. M., Gaddamanugu, G. K., Paraselli, B. R., & Baran, P. S. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c03592 · Cited by 172
Transcriptional regulators of the human multidrug resistance 1 gene: recent views
Labialle, S., Gayet, L., Marthinet, E., Rigal, D., & Baggetto, L. G. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01156-5 · Cited by 171
Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells.
Fojo, A. T., Whang-Peng, J., Gottesman, M. M., & Pastan, I. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.22.7661 · Cited by 170
Lee, S.-W., Yun, M.-H., Jeong, S. W., In, C.-H., Kim, J.-Y., Seo, M.-H., Pai, C.-M., & Kim, S.-O. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.012 · Cited by 169
The UCSF-FDA TransPortal: A Public Drug Transporter Database
Morrissey, K. M., Wen, C. C., Johns, S. J., Zhang, L., Huang, S.-M., & Giacomini, K. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.44 · Cited by 169
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Wee, Z. N., Yatim, S. M. J. M., Kohlbauer, V. K., Feng, M., Goh, J. Y., Bao, Y., Lee, P. L., Zhang, S., Wang, P. P., Lim, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms9746 · Cited by 168
Yang, R., Xiu, H., Zhou, Q., Sun, L., Mu, H., Li, H., Wang, S., Li, X., Chen, W., & Dong, J. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4809836 · Cited by 166
Chronic Oxidative Stress Increases Growth and Tumorigenic Potential of MCF-7 Breast Cancer Cells
Mahalingaiah, P. K. S., & Singh, K. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087371 · Cited by 164
Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes
Galletti, E., Magnani, M., Renzulli, M. L., & Botta, M. (2007) · ChemMedChem · doi:10.1002/cmdc.200600308 · Cited by 164
The complexity of integrins in cancer and new scopes for therapeutic targeting
Hamidi, H., Pietilä, M., & Ivaska, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.312 · Cited by 164
Epigenetic Switch–Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer
Deblois, G., Tonekaboni, S. A. M., Grillo, G., Martínez, C., Kao, Y. I., Tai, F., Ettayebi, I., Fortier, A.-M., Savage, P., Fedor, A. N., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1493 · Cited by 164
DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons
Wilhelm, T., Said, M., & Naim, V. (2020) · Genes · doi:10.3390/genes11060642 · Cited by 164
Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
Zhitomirsky, B., & Assaraf, Y. G. (2017) · Oncotarget · doi:10.18632/oncotarget.15155 · Cited by 163
Self-citationMarín‐Aguilera, M., Codony‐Servat, J., Reig, Ò., Lozano, J. J., Fernández, P. L., Pereira, M. V., Jiménez, N., Donovan, M. J., Puig, P., Mengual, L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0775 · Cited by 162
Ploussard, G., Terry, S., Maillé, P., Allory, Y., Sirab, N., Kheuang, L., Soyeux, P., Nicolaiew, N., Coppolani, E., Paule, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1447 · Cited by 161
Tubulin Post-Translational Modifications and Microtubule Dynamics
Wloga, D., Joachimiak, E., & Fabczak, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102207 · Cited by 161
Boyerinas, B., Park, S., Murmann, A. E., Gwin, K., Montag, A. G., Zillhardt, M., Hua, Y., Lengyel, E., & Peter, M. E. (2012) · International Journal of Cancer · doi:10.1002/ijc.26190 · Cited by 159
Peng, X., Gong, F., Chen, Y., Jiang, Y., Liu, J., Yu, M., Zhang, S., Wang, M., Xiao, G., & Liao, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.297 · Cited by 159
Differential distribution of beta-tubulin isotypes in cerebellum.
Burgoyne, R. D., Cambray-Deakin, M. A., Lewis, S. A., Sarkar, S., & Cowan, N. J. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03074.x · Cited by 158
Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer
Ji, L., Li, H., Gao, P., Shang, G., Zhang, D. D., Zhang, N., & Jiang, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063404 · Cited by 158
Robey, R. W., Shukla, S., Finley, E. M., Oldham, R. K., Barnett, D., Ambudkar, S. V., Fojo, T., & Bates, S. E. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.12.001 · Cited by 158
Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis.
Mialhe, A., Lafanéchère, L., Treilleux, I., Peloux, N., Dumontet, C., Bremond, A. G., Panh, M. H., Payan, R., Wehland, J., Margolis, R. L., et al. (2001) · PubMed · Cited by 157
Dantzig, A., Law, K., Cao, J., et al. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373903 · Cited by 156
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Self-citationMeeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 156
Do β-tubulin mutations have a role in resistance to chemotherapy?
Berrieman, H. K., Lind, M., & Cawkwell, L. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01411-1 · Cited by 153
Vasconcelos, M. H., Caires, H. R., Ābols, A., Xavier, C. P. R., & Linē, A. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100647 · Cited by 153
Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors
Dastvan, R., Mishra, S., Peskova, Y. B., Nakamoto, R. K., & Mchaourab, H. S. (2019) · Science · doi:10.1126/science.aav9406 · Cited by 151
A β-Tubulin Leucine Cluster Involved in Microtubule Assembly and Paclitaxel Resistance
Gonzalez‐Garay, M. L., Chang, L., Cabral, F., Blade, K. L., & Menick, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23875 · Cited by 150
Stathmin 1: a novel therapeutic target for anticancer activity
Rana, S. R., Maples, P. B., Senzer, N. N., & Nemunaitis, J. J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.9.1461 · Cited by 149
Expression of class III β‐tubulin reduces microtubule assembly and confers resistance to paclitaxel
Hari, M., Yang, H., Zeng, C., Canizales, M., & Cabral, F. (2003) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.10132 · Cited by 148
Neeße, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W., Richards, F. M., Ellenrieder, V., Jodrell, D. I., & Tuveson, D. A. (2013) · Gut · doi:10.1136/gutjnl-2013-305559 · Cited by 147
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 145
Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint
Rueff, J., & Rodrigues, A. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_1 · Cited by 144
Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia
Syu, J.-P., Chi, J., & Kung, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7406 · Cited by 141
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 141
Self-citationFitzpatrick, J. M., & de Wit, R. (2013) · European Urology · doi:10.1016/j.eururo.2013.07.022 · Cited by 140
Zhou, J., Gupta, K. K., Yao, J. L., Ye, K., Panda, D., Giannakakou, P., & Joshi, H. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203927200 · Cited by 139
Yu, Y., Gaillard, S. L., Phillip, J. M., Huang, T., Pinto, S. M., Tessarollo, N. G., Zhang, Z., Pandey, A., Wirtz, D., Ayhan, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.009 · Cited by 138
The Functional Role of P-Glycoprotein in the Blood–Brain Barrier
van Asperen, J., Mayer, U., van Tellingen, O., & Beijnen, J. H. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9701364 · Cited by 138
Vilaboa, N. E., Galán, A., Troyano, A., de Blas, E., & Aller, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909136199 · Cited by 136
van Soest, R. J., de Morrée, E. S., Kweldam, C. F., de Ridder, C. M. A., Wiemer, E. A. C., Mathijssen, R. H. J., de Wit, R., & van Weerden, W. M. (2014) · European Urology · doi:10.1016/j.eururo.2014.11.033 · Cited by 135
The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review
Akhtar, N., Ahad, A., Khar, R. K., Jaggi, M., Aqil, M., Iqbal, Z., Ahmad, F. J., & Talegaonkar, S. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.561784 · Cited by 133
Huang, D., Duan, H., Huang, H., Tong, X., Han, Y. K., Ru, G., Qu, L., Shou, C., & Zhao, Z. (2016) · Scientific Reports · doi:10.1038/srep20502 · Cited by 133
FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance
Khongkow, P., Karunarathna, U., Khongkow, M., Gong, C., Gomes, A., Yagüe, E., Monteiro, L. J., Kongsema, M., Zona, S., Man, E. P. S., et al. (2013) · Oncogene · doi:10.1038/onc.2013.457 · Cited by 132
Yuan, J., Krämer, A., Matthess, Y., Yan, R., Spänkuch, B., Gätje, R., Knecht, R., Kaufmann, M., & Strebhardt, K. (2005) · Oncogene · doi:10.1038/sj.onc.1209202 · Cited by 131
Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities
Rohena, C. C., & Mooberry, S. L. (2014) · Natural Product Reports · doi:10.1039/c3np70092e · Cited by 131
Stathmin Activity Influences Sarcoma Cell Shape, Motility, and Metastatic Potential
Belletti, B., Nicoloso, M. S., Schiappacassi, M., Berton, S., Lovat, F., Wolf, K., Canzonieri, V., D’Andrea, S., Zucchetto, A., Friedl, P., et al. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-09-0894 · Cited by 131
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129
Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M., & Waes, C. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1393 · Cited by 129
Cai, Y., Zheng, Y., Gu, J., Wang, S., Wang, N., Yang, B., Zhang, F., Wang, D., Fu, W., & Wang, Z. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0669-8 · Cited by 128
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer
Lam (2009) · International Journal of Oncology · doi:10.3892/ijo_00000313 · Cited by 127
Formenti, S. C., Volm, M. D., Skinner, K. A., SPICER, D. V., Cohen, D., Perez, E. A., Bettini, A., Groshen, S. G., Gee, C., Florentine, B. D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.132 · Cited by 127
P‐glycoprotein: So Many Ways to Turn It On
Callaghan, R., Crowley, E. H., Biochem, M., Potter, S., & Kerr, I. D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007311568 · Cited by 126
Zhitomirsky, B., Yunaev, A., Kreiserman, R., Kaplan, A., Stark, M., & Assaraf, Y. G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1227-0 · Cited by 126
Self-citationSusceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux
Chavanpatil, M. D., Patil, Y. B., & Panyam, J. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.045 · Cited by 124
Risinger, A. L., Jackson, E. M., Polin, L., Helms, G. L., LeBoeuf, D. A., Joe, P. A., Hopper-Borge, E. A., Ludueña, R. F., Kruh, G. D., & Mooberry, S. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2037 · Cited by 123
Delivery of Nanoparticle-Based Radiosensitizers for Radiotherapy Applications
Boateng, F., & Ngwa, W. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010273 · Cited by 122
Němcová‐Fürstová, V., Kopperová, D., Balušíková, K., Ehrlichová, M., Brynychová, V., Václavíková, R., Daniel, P., Souček, P., & Kovár̆, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.020 · Cited by 121
The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
Hou, Y., Zhu, Q., Li, Z., Peng, Y., Yu, X., Yuan, B., Liu, Y., Liu, Y., Yin, L., Peng, Y., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.53 · Cited by 121
Arnst, K. E., Wang, Y., Hwang, D., Xue, Y., Costello, T., Hamilton, D. J., Chen, Q., Yang, J., Park, F., Dalton, J. T., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0577 · Cited by 121
Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., Seino-Noda, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0958 · Cited by 120
Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs
Chinnappan, M., Srivastava, A., Amreddy, N., Razaq, M., Pareek, V., Ahmed, R. A., Mehta, M., Peterson, J. E. G., Munshi, A., & Ramesh, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.004 · Cited by 120
Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region
Raspaglio, G., Filippetti, F., Prislei, S., Penci, R., Maria, I. D., Cicchillitti, L., Mozzetti, S., Scambia, G., & Ferlini, C. (2007) · Gene · doi:10.1016/j.gene.2007.11.015 · Cited by 119
Rocha, C., Papon, L., Cacheux, W., Sousa, P. M., Lascano, V., Tort, O., Giordano, T., Vacher, S., Lemmers, B., Mariani, P., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201488466 · Cited by 119
Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
Mittal, K., Donthamsetty, S., Kaur, R., Yang, C., Gupta, M. V., Reid, M. D., Choi, D. H., Rida, P. C. G., & Aneja, R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.78 · Cited by 119
Nanomedicine to target multidrug resistant tumors
Lepeltier, É., Rijo, P. M., Rizzolio, F., Popovtzer, R., Petrikaitė, V., Assaraf, Y. G., & Passirani, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100704 · Cited by 118
Self-citationHuisman, C., Ferreira, C. G., Bröker, L. E., Rodríguez, J. A., Smit, E. F., Postmus, P. E., Kruyt, F. A. E., & Giaccone, G. (2002) · PubMed · Cited by 117
Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., Scheper, R. J., & Baccarani, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01172.x · Cited by 116
Goel, H. L., Gritsko, T. M., Pursell, B. M., Chang, C., Shultz, L. D., Greiner, D. L., Norum, J. H., Toftgård, R., Shaw, L. M., & Mercurio, A. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.059 · Cited by 116
Ekoff, M., Kaufmann, T., Engström, M., Motoyama, N., Villunger, A., Jönsson, J., Strasser, A., & Nilsson, G. P. (2007) · Blood · doi:10.1182/blood-2007-02-073957 · Cited by 114
Expression of a human multidrug resistance gene in ovarian carcinomas.
Bourhis, J., Goldstein, L. J., RIOU, G. F., et al. (1989) · PubMed · Cited by 114
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
Konecny, G. E., Venkatesan, N., Yang, G., Dering, J., Ginther, C., Finn, R. S., Rahmeh, M., Fejzo, M. S., Toft, D. O., Jiang, S.-W., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604278 · Cited by 112
HIV-1 Protease Inhibitor, Ritonavir
Ikezoe, T., Hisatake, Y., Takeuchi, T., Ohtsuki, Y., Yang, Y., SAID, J. W., Taguchi, H., & Koeffler, H. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2677 · Cited by 112
Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies
Dumontet, C., Jordan, M. A., & Lee, F. Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0986 · Cited by 112
Abraham, J., Guo, Q. J., Dorling, L., Tyrer, J. P., Ingle, S., Hardy, R., Vallier, A.-L., Hiller, L., Burns, R., Jones, L. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3232 · Cited by 110
Ganesh, T., Guza, R., Bane, S., Ravindra, R., Shanker, N., Lakdawala, A. S., Snyder, J. P., & Kingston, D. G. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403459101 · Cited by 110
Tada, Y., Wada, M., Migita, T., Nagayama, J., Hinoshita, E., Mochida, Y., Maehara, Y., Tsuneyoshi, M., Kuwano, M., & Naito, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.10246 · Cited by 109
Huang, Y., Ibrado, A. M., Reed, J., Bullock, G., Ray, S. K., Tang, C., & Bhalla, K. N. (1997) · Leukemia · doi:10.1038/sj.leu.2400557 · Cited by 108
Zhou, D.-C., Zittoun, R., & Marie, J. (1995) · PubMed · Cited by 107
The Seco-Taxane IDN5390 Is Able to Target Class III β-Tubulin and to Overcome Paclitaxel Resistance
Ferlini, C., Raspaglio, G., Mozzetti, S., Cicchillitti, L., Filippetti, F., Gallo, D., Fattorusso, C., Campiani, G., & Scambia, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3065 · Cited by 107
Alterations of β‐tubulin isotypes in breast cancer cells resistant to docetaxel
Shalli, K., Brown, I. M., Heys, S. D., & Schofield, C. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-3178fje · Cited by 107
Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance
Ayers, D., & Vandesompele, J. (2017) · Genes · doi:10.3390/genes8030095 · Cited by 107
Chen, D., Lin, X., Zhang, C., Liu, Z., Chen, Z., Li, Z., Wang, J., Li, B., Hu, Y., Dong, B., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0132-2 · Cited by 107
Savas, Ü., Griffin, K. J., & Johnson, E. F. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.5.851 · Cited by 106
CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway
Wang, L., Zhang, F., Cui, J., Chen, L., Chen, Y., & Liu, B. (2018) · Oncology Reports · doi:10.3892/or.2018.6311 · Cited by 106
Fang, X., Zhang, C., Zhang, C., Cai, Y., Yu, Z., Huang, Z., Li, W., & Zhang, W. (2019) · Stem Cells International · doi:10.1155/2019/7378594 · Cited by 106
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
van der Kolk, D. M., de Vries, E. G. E., Putten, W. J. V., Verdonck, L. F., Ossenkoppele, G. J., Verhoef, G. E. G., & Vellenga, E. (2000) · PubMed · Cited by 105
Reshkin, S. J., Bellizzi, A., Cardone, R. A., Tommasino, M., Casavola, V., & Paradiso, A. (2003) · PubMed · Cited by 102
Tumor targeting by conjugation of DHA to paclitaxel
Bradley, M. O., Swindell, C. S., Anthony, F. H., Witman, P. A., Devanesan, P. D., Webb, N. L., Baker, S. D., Wolff, A. C., & Donehower, R. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00321-2 · Cited by 101
Kuroda, K., Liu, H., Kim, S., Guo, M., Navarro, V., & Bander, N. H. (2009) · The Prostate · doi:10.1002/pros.21004 · Cited by 101
Alli, E., Yang, J., Ford, J. M., & Hait, W. N. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029702 · Cited by 100
Mechanisms of Resistance to Cabazitaxel
Durán, G. E., Wang, Y. C., Francisco, E. B., Rose, J. C., Martinez, F. J., Coller, J., Brassard, D., Vrignaud, P., & Sikic, B. I. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0155 · Cited by 100
Advances and Challenges in Basic and Translational Research on Clusterin
Trougakos, I. P., Djeu, J. Y., Gonos, E. S., & Boothman, D. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2912 · Cited by 99
Design, Synthesis, and Biological Evaluation of New-Generation Taxoids
Ojima, I., Chen, J., Sun, L. D., Borella, C. P., Wang, L., Miller, M. L., Lin, S., Geng, X., Kuznetsova, L. V., Qu, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800086e · Cited by 98
Human Mutations That Confer Paclitaxel Resistance
Yin, S., Bhattacharya, R., & Cabral, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0674 · Cited by 98
Suh, Y., Jo, S., Lee, H., & Lee, C. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2808 · Cited by 97
Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance
Najafi, M., Mortezaee, K., & Ahadi, R. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.076 · Cited by 97
Resistance to docetaxel‐induced apoptosis in prostate cancer cells by p38/p53/p21 signaling
Gan, L., Wang, J., Xu, H., & Yang, X. (2011) · The Prostate · doi:10.1002/pros.21331 · Cited by 96
Activation of human multidrug resistance-1 gene promoter in response to heat shock stress
Miyazaki, M., Kohno, K., Uchiumi, T., Tanimura, H., Matsuo, K.-I., Nasu, M., & Kuwano, M. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91248-o · Cited by 95
Cui, D., Dai, J., Keller, J. M., Mizokami, A., Xia, S., & Keller, E. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0242 · Cited by 95
Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo
Parekh, A., Das, S., Parida, S., Das, C. K., Dutta, D., Mallick, S. K., Wu, P.-H., Kumar, B. N. P., Bharti, R., Dey, G., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0272-6 · Cited by 95
Reese, M., Sánchez‐Pedregal, V. M., Kubíček, K., Meiler, J., Blommers, M. J. J., Griesinger, C., & Carlomagno, T. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200604505 · Cited by 94
Microtubule-Associated Proteins and Their Essential Roles During Mitosis
Maiato, H., Sampaio, P., & Sunkel, C. E. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)41002-x · Cited by 93
Hendrikx, J. J. M. A., Lagas, J. S., Rosing, H., Schellens, J. H. M., Beijnen, J. H., & Schinkel, A. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.27912 · Cited by 93
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line
Chan, K.-T., & Lung, M. L. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0767-4 · Cited by 93
Brito, D. A., & Rieder, C. L. (2008) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20316 · Cited by 93
Expression of multidrug resistance protein gene in patients with glioma chemotherapy
Abe, T., Mori, T., Wakabayashi, Y., Nakagawa, M., Cole, S. P. C., Koike, K., Kuwano, M., & Hori, S. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005954406809 · Cited by 92
Negishi, T., Koizumi, F., Uchino, H., Kuroda, J.-I., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603311 · Cited by 92
Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma
Azzarito, T., Venturi, G., Cesolini, A., & Fais, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.017 · Cited by 91
The emerging role of noncoding RNAs in colorectal cancer chemoresistance
Wei, L., Wang, X., Lv, L., Zheng, Y., Zhang, N., & Yang, M. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00466-8 · Cited by 91
Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833
Chico, I. M., Kang, M. H., Bergan, R. C., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R. W., Choyke, P. L., Merino, M. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.832 · Cited by 90
Zhao, F., Siu, M. K. Y., Jiang, L., Tam, K. F., Ngan, H. Y. S., Le, X. F., Wong, O. G. W., Wong, E. S. Y., Gomes, A. R., Bella, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113478 · Cited by 88
Januchowski, R., Sterzyńska, K., Zawierucha, P., Ruciński, M., Świerczewska, M., Partyka, M., Bednarek-Rajewska, K., Brązert, M., Nowicki, M. O., Zabel, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18278 · Cited by 87
Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?
Mitchison, T. J., Pineda, J. J., Shi, J., & Florian, S. (2017) · Open Biology · doi:10.1098/rsob.170182 · Cited by 87
Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10−/− Mice
Hopper-Borge, E. A., Churchill, T., Paulose, C., Nicolas, É., Jacobs, J. D., Ngo, O., Kuang, Y., Grinberg, A., Westphal, H., Chen, Z., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3623 · Cited by 86
The β isotypes of tubulin in neuronal differentiation
Guo, J., Walss‐Bass, C., & Ludueña, R. F. (2010) · Cytoskeleton · doi:10.1002/cm.20455 · Cited by 86
Perego, P., Romanelli, S., Carenini, N., Magnani, I., Leone, R., Bonetti, A. V., Paolicchi, A., & Zunino, F. (1998) · Annals of Oncology · doi:10.1023/a:1008265012435 · Cited by 86
Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Bumbaca, B., & Li, W. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.007 · Cited by 85
Cretella, D., Fumarola, C., Bonelli, M. A., Alfieri, R. R., Monica, S. L., Digiacomo, G., Cavazzoni, A., Galetti, M., Generali, D., & Petronini, P. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-49484-4 · Cited by 85
Ganguly, A., Yang, H., & Cabral, F. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1109 · Cited by 84
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer
Crea, F., Serrat, M. A. D., Hurt, E. M., Thomas, S. B., Danesi, R., & Farrar, W. L. (2010) · International Journal of Cancer · doi:10.1002/ijc.25522 · Cited by 83
Zhang, H., Xie, C., Yue, J., Jiang, Z., Zhou, R., Xie, R., Wang, Y., & Wu, S. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22581 · Cited by 83
Advani, R. H., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001) · PubMed · Cited by 81
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
Dorr, R. T., Karanes, C., Spier, C. M., Grogan, T. M., Greer, J. P., Moore, J., Weinberger, B., Schiller, G. J., Pearce, T. E., Litchman, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1589 · Cited by 81
Sorcin Induces a Drug-Resistant Phenotype in Human Colorectal Cancer by Modulating Ca2+ Homeostasis
Maddalena, F., Laudiero, G., Piscazzi, A., Secondo, A., Scorziello, A., Lombardi, V., Matassa, D. S., Fersini, A., Neri, V., Esposito, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2172 · Cited by 81
Zhou, Z., Zhang, L., Xie, B., Wang, X., Yang, X., Ding, N., Zhang, J., Liu, Q., Tan, G., Feng, D., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.008 · Cited by 81
Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles
Engelberg, S., Modrejewski, J., Walter, J., Livney, Y. D., & Assaraf, Y. G. (2018) · Oncotarget · doi:10.18632/oncotarget.24772 · Cited by 81
Self-citationSnaebjornsson, M. T., & Schulze, A. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0065-6 · Cited by 80
Src family kinases and paclitaxel sensitivity
Le, X.-F., & Bast, Jr. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.16430 · Cited by 79
Šale, S., Sung, R. K., Shen, P., Yu, K. M., Wang, Y. C., Durán, G. E., Kim, J.-H., Fojo, T., Oefner, P. J., & Sikic, B. I. (2002) · PubMed · Cited by 79
Lee, H.-S., Lee, N., Kouprina, N., Kim, J., Kagansky, A., Bates, S. E., Trepel, J. B., Pommier, Y. G., Sackett, D. L., & Larionov, V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1617 · Cited by 79
Kingston, D. G. I., Molinero, A. A., & Rimoldi, J. M. (1993) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-7091-9242-9_1 · Cited by 78
Alexa‐Stratulat, T., Pešić, M., Gašparović, A. Č., Trougakos, I. P., & Riganti, C. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100643 · Cited by 78
Su, D., Smith, S. M., Preti, M., Schwartz, P. E., Rutherford, T., Menato, G., Danese, S., Ma, S., Yu, H., & Katsaros, D. (2009) · Cancer · doi:10.1002/cncr.24282 · Cited by 77
Januchowski, R., Zawierucha, P., Ruciński, M., Andrzejewska, M., Wojtowicz, K., Nowicki, M. O., & Zabel, M. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.02.002 · Cited by 76
Furlong, F. M., Fitzpatrick, P., O’Toole, S. A., Phelan, S., McGrogan, B., Maguire, A. A., O’Grady, A., Gallagher, M. F., Prencipe, M., McGoldrick, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.3035 · Cited by 76
Lee, K. M., Cao, D., Itami, A., Pour, P. M., Hruban, R. H., Maitra, A., & Ouellette, M. M. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02792.x · Cited by 75
Maddalena, F., Sisinni, L., Lettini, G., Condelli, V., Matassa, D. S., Piscazzi, A., Amoroso, M. R., Torre, G. L., Esposito, F., & Landriscina, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.04.009 · Cited by 75
Phosphorylation of βIII-Tubulin
KHAN, I. A., & Ludueña, R. F. (1996) · Biochemistry · doi:10.1021/bi951247p · Cited by 74
Lindamulage, I. K. S., Vu, H.-Y. T., Karthikeyan, C., Knockleby, J., Lee, Y.-F., Trivedi, P., & Lee, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-10972-0 · Cited by 74
Zhao, Y., Chen, S., Jiao, J., Sun, K., & Zong, Z. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87526 · Cited by 72
Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5
Exertier, P., Javerzat, S., Wang, B., Franco, M., Herbert, J. M. J., Platonova, N., Winandy, M., Pujol, N., Nivelles, O., Orménèse, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1490 · Cited by 71
βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer
McCarroll, J. A., Sharbeen, G., Liu, J., Youkhana, J., Goldstein, D., McCarthy, N., Limbri, L. F., Dischl, D., Ceyhan, G. O., Erkan, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2946 · Cited by 71
Freedman, H., Huzil, J. T., Luchko, T., Ludueña, R. F., & Tuszyński, J. A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci8003336 · Cited by 71
Serpico, A. F., Visconti, R., & Grieco, D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2567-0 · Cited by 71
Tumbarello, D. A., Temple, J., & Brenton, J. D. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-36 · Cited by 70
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein
Weidner, L. D., Fung, K.-L., Kannan, P., Moen, J. K., Kumar, J. S., Mulder, J., Innis, R. B., Gottesman, M. M., & Hall, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067785 · Cited by 70
Ibrado, A. M., Kim, C. N., & Bhalla, K. N. (1998) · Leukemia · doi:10.1038/sj.leu.2401218 · Cited by 70
Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma
Chang, I., Mitsui, Y., Fukuhara, S., Gill, A., Wong, D. K., Yamamura, S., Shahryari, V., Tabatabai, Z. L., Dahiya, R., Shin, D. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3484 · Cited by 68
Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III β‐tubulin
Katsetos, C. D., Dráberová, E., Legido, A., Dumontet, C., & Dráber, P. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21870 · Cited by 68
Tcherniuk, S. O., Skoufias, D. A., Labrière, C., Rath, O., Guéritte, F., Guillou, C., & Kozielski, F. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201003254 · Cited by 68
Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance
Yabuki, N., Sakata, K., Yamasaki, T., Terashima, H., Mio, T., Miyazaki, Y., Fujii, T., & Kitada, K. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.07.020 · Cited by 68
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationLi, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
Du, R., You, Q., Liu, J., Wang, C., Zhu, L., & Yang, Y. (2023) · Nano Research · doi:10.1007/s12274-023-6105-0 · Cited by 19
Metadata
- Authors
- Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 54
- Pages
- 100742
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3120588454
- Cited by
- 385
- References
- 539
- FWCI
- 18.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.